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ABSTRACT
Chronic graft-versus-host disease (cGvHD) and systemic sclerosis (scleroderma [SSc]) share clinical charac-
teristics, including skin and internal organ fibrosis. Fibrosis, regardless of the cause, is characterized by
extracellular matrix deposition, of which collagen type I is the major constituent. The progressive accumula-
tion of connective tissue results in destruction of normal tissue architecture and internal organ failure. In both
SSc and cGvHD, the severity of skin and internal organ fibrosis correlates with the clinical course of the
disease. Thus, there is an unmet need for well-tolerated antifibrotic therapy. Halofuginone is an inhibitor of
collagen type I synthesis in cells derived from various tissues and species and in animal models of fibrosis in
which excess collagen is the hallmark of the disease. Halofuginone decreased collagen synthesis in the tight
skin mouse (Tsk) and murine cGvHD, the 2 experimental systems that show many features resembling those
of human GvHD. Inhibition of collagen synthesis by halofuginone is achieved by inhibiting transforming
growth factor –dependent Smad3 phosphorylation. Dermal application of halofuginone caused a decrease in
collagen content at the treated site of a cGvHD patient, and reduction in skin scores was observed in a pilot
study with SSc patients. The results of the human studies provide basis for using halofuginone treatment for
dermal fibrosis. As a first step toward future treatment of internal organ involvement, an oral administration
study was performed in which halofuginone was well tolerated and plasma levels surpassed the predicted
therapeutic exposure.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Tissue ﬁbrosis, including pulmonary, renal, hepatic,
and cardiac ﬁbrosis, is manifested as excessive production
of connective tissues that results in destruction of normal
tissue architecture and function. This review focuses
mainly on the antiﬁbrotic potential of a novel and prom-
ising agent, halofuginone [1-3], with emphasis on
chronic graft-versus-host disease (cGvHD) and systemic
sclerosis (SSc) that share clinical characteristics including
skin and internal organ ﬁbrosis.
FIBROSIS
Fibrosis represents the response of the organ to
diverse acute and chronic insults. Fibrosis, regardless
of the cause, is characterised by an increase in extra-
cellular matrix (ECM) constituents, of which collagen
type I is the major one. Although the synthesis and
systemic accumulation of collagen and noncollagen
matrix proteins are essential for normal tissue devel-
opment and wound repair, excessive matrix accumu-
lation leads to pathologic ﬁbrosis. The pathogenesis of
the ﬁbrotic disorders is similar, regardless of the tis-
sue, and the cellular mechanism of ﬁbrosis is shared
among the various insults. This mechanism in many
aspects mirrors the scarring and wound-healing pro-
cesses, but the persistent activation of the genes en-
coding for the ECM proteins distinguish controlled
wound repair from the uncontrolled connective tissue
deposition that results in ﬁbrosis. In addition to the
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ECM synthesis and deposition, and not less important
to the progression of ﬁbrosis, there are inadequate
degradation, removal, and clearance of the ECM. In
the extracellular space, matrix degradation occurs pre-
dominantly as a consequence of the actions of the
matrix metalloproteinases (MMPs) and the tissue in-
hibitors of metalloproteinases (TIMPs) that closely
regulates MMP activity. The MMPs and TIMPs play
a crucial role in the ﬁne regulation of the ECM turn-
over that is altered in most pathologic states associated
with ﬁbrosis [4,5].
The ﬁbrotic reaction is thought to involve the
stimulative response of tissue cells that results in in-
creased cell proliferation as well as ECM deposition.
In some cases, such as skin, pulmonary, and kidney
ﬁbrosis, ﬁbroblasts are thought to play a pivotal role in
collagen synthesis [6,7]. In the liver and pancreas,
other resident cells, the stellate cells, were found to be
the cellular source of collagen and other ECM mole-
cules [8,9]. Regardless of their origin, and in response
to the ﬁbrogenic stimulus, the cells that are usually
quiescent with low proliferation rates differentiate
into myoﬁbroblast-like cells, with high proliferative
capacity and an ability to synthesize large numbers of
ECM molecules, especially collagen type I [10,11].
CGVHD AND SSC
cGvHD is a major late complication of allogeneic
stem cell transplantation (alloSCT) and is a principal
cause of morbidity and nonrelapse mortality. As a
result of increasing numbers of unrelated and mis-
matched alloSCT and of the change from bone mar-
row to peripheral blood grafts, the number of patients
with cGvHD has increased [12]. Chronic GvHD may
develop in 25% to 45% of recipients of alloSCT from
matched, related siblings depending upon age, and its
frequency may increase to 40% to 70% in patients
receiving alloSCT from matched, unrelated donors
[13,14]. The incidence is signiﬁcantly lower in pa-
tients receiving human umbilical cord blood grafts or
haploidentical CD34 puriﬁed grafts [15,16]. Chronic
GvHD may develop as an extension of acute GvHD
(progressive onset), after resolution of acute GvHD
(quiescent onset), or without proceeding acute GvHD
(de novo onset). Chronic GvHD is categorized as ei-
ther limited (localized skin and/or hepatic involve-
ment) or extensive (diffuse skin and/or multiorgan
involvement); the latter is associated with a more se-
vere prognosis [17]. The introduction of low-intensity
conditioning (LIC) and nonmyeloablative alloSCT
has not resulted in a reduction in the frequency of
cGvHD [18]. cGvHD usually develops more than 100
days after transplantations, with increased frequency
in patients receiving peripheral blood stem cell grafts
and in those undergoing LIC alloSCT [12,18].
Chronic GvHD typically resembles connective tissue
autoimmune-like immunologic disorder such as SSc
characterized by lichenoid or sclerodermoid lesions of
the skin, along with joint contractors with eosino-
philia, circulating autoantibodies, hypergammaglobu-
linemia, and plasmacytosis of viscera and lymph nodes
[17].
The skin includes papulosquamous dermatitis,
plaques, desquamation, depigmentation and vetiligo,
and thickened reticular dermis because of increased
synthesis of collagen [19]. Cutaneous appendages be-
come encased in collagen and tend to disappear.
There is occurrence of a variable perivascular and
interstitial inﬂammatory cell inﬁltrate, composed pre-
dominantly of lymphocytes and occasional plasma
cells [20]. Less-frequent skin ﬁndings include poi-
kiloderma, reticulated hyperpigmentation, alopecia,
dystrophic nails, leucoderma bullae, discoid lupus er-
ythematosus, and photosensitivity. The pathophysio-
logic mechanism involves autoreactive lymphocytes
and cytokine dysregulation [21,22]. Current therapeu-
tic options are limited. Fewer than 20% of patients
with untreated extensive cGvHD with Karnofsky per-
formance scores 70% survive [17]. Currently, corti-
costeroids, alone or in combination with cyclosporine,
remain the treatment of choice for established
cGvHD. Other therapeutic options that have been
tried include thalidomide, mycophenolate mofetil, ta-
crolimus, rapamycin, clofazimine, etretinate, hydroxy-
chloroquine, ursodeoxycholic acid, penicillamine, cy-
clophenile, and nedocromil sodium, as well as medical
procedures such as total lymphoid irradiation, photo-
therapy (PUVA), and extracorporeal phototherapy
[23].
SSc is a connective tissue disease with an unknown
cause. As an autoimmune disease involving cellular
and humoral immunity, it affects multiple organ sys-
tems, including skin, gastrointestinal tract, lungs, kid-
neys, and heart. The severity of skin and internal
organ involvement correlates with the clinical course
of the disease [24]. According to the degree of skin
involvement, SSc can be classiﬁes as limited cutaneous
SSc or diffuse cutaneous SSc. Limited cutaneous SSc,
which is slowly progressive and frequently associated
with anticentromere antibodies, is characterized by
sclerodactyly or acrosclerosis, with distal involvement
of the extremities with or without facial involvement,
Raynaud’s phenomenon, dysphagia, calcinosis cutis,
and telangiectasis [24]. The most severe systemic
complications are pulmonary hypertension and biliary
cirrhosis. Diffuse cutaneous SSc is more severe and
shows proximal involvement of the extremities, trunk,
or both, and is associated with pulmonary interstitial
ﬁbrosis, renal crises, and gastrointestinal involvement
(dysphagia, hypomotility, and other disorders). Dif-
fuse cutaneous SSc is frequently associated with Scl-70
(antitopoisomerase) and nucleolar autoantibodies
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(polymerase I and III, ﬁbrillarin). The mechanism of
ﬁbrosis in SSc is not fully understood, although it is
known that soluble mediators (transforming growth
factor  [TGF-], platelet-derived growth factor, in-
terleukin-4 and -6, tumor necrosis factor  [TNF-]
can be secreted by lymphocytes, monocytes, and en-
dothelial cells and can affect the behavior of ﬁbroblast
growth, proliferation, collagen synthesis, and chemo-
taxis [25,26]. The excessive tissue ﬁbrosis is caused by
expansion of ﬁbrogeneic clones of tissue ﬁbroblasts,
which behave relatively autonomously and overex-
press genes encoding ECM components, leading to
excessive deposition of collagen and other ECM pro-
teins in skin and internal organs and blood vessels
[27]. Present therapies are directed to improve periph-
eral blood circulation with vasodilators and antiplate-
let aggregation drugs, to prevent the synthesis and
release of harmful cytokines by means of immunosup-
pressants, and to inhibit or reduce ﬁbrosis with agents
that interfere with collagen synthesis or enhance col-
lagenase production. Autologous stem cell transplan-
tation was performed after immunoablative pretreat-
ment in diffuse SSc patients with involvement of 1 or
more internal organs [28]. The mortality rate was
17%, in part caused by interstitial pneumonitis, pos-
sibly as a result of an exaggerated response to total
body irradiation. Seventy percent of patients had over
25% improvement in their skin score and stabilization
of lung function. This is still an experimental therapy
and currently limited to patients with severe, progres-
sive, life-threatening disease [29]. The treatment of
SSc remains a challenge to the clinician, and there is
an unmet need for new therapies [30].
HALOFUGINONE
For centuries, the roots of Dichroa febrifuga, a
saxifragaceous plant, have been employed in China in
the treatment of malarial fever. Febrifugine and its
stereoisomere, isofebrifugine, were identiﬁed as the
active components against malaria. Febrifugine ana-
logues bearing a modiﬁed or unmodiﬁed 4-quinazoli-
none ring are active, whereas those produced through
the modiﬁcation of the side chain attached to the N-3
position of the 4-quinazolinone are ineffective [31].
Halofuginone (7-bromo-6-chloro-3-[3-(3-hydroxy-
2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone) is
one of the febrifugine analogoues used worldwide in
commercial poultry production for coccidiosis [32].
HALOFUGINONE AND THE COLLAGEN CONNECTION
Serendipity was the driving force beyond the ﬁnd-
ing that halofuginone has an inhibitory effect on col-
lagen synthesis [1-3]. In vitro halofuginone was found
to inhibit collagen type I synthesis but not that of type
II [33] or III [34]. Halofuginone inhibited collagen
synthesis in a variety of cells, including primary cul-
tures of mouse skin ﬁbroblasts, avian growth plate
chondrocytes, a transformed rat embryo cell line, vas-
cular smooth muscle cells, bovine aortic endothelial
cells, and rat liver stellate cells [33-36], all of which
produce and secrete collagen type I. In animal models
of ﬁbrosis in which excess collagen is the hallmark of
the disease, administration of halofuginone prevented
the increase in collagen synthesis and collagen 1(I)
gene expression. These models include rat postopera-
tional abdominal and uterine horn adhesions [37,38],
rat urethral stricture formation [39], thioacetamide-
and dimethylnitrosamine-induced rat cirrhosis [36,40],
rat pulmonary ﬁbrosis after bleomycin treatment [41],
and tight skin (Tsk) and cGvHD-afﬂicted mice [42-
44]. Inhibition was independent of the route of ad-
ministration (intraperitoneally, administered locally,
or given orally).
The reduction in collagen synthesis by halofugi-
none appears not to be a direct effect of halofuginone
on the collagen 1(I) promoter but rather dependent
on new protein synthesis, because simultaneous treat-
ment of ﬁbroblasts with protein synthesis inhibitors
such as cycloheximide or actinomycin D blocks the
suppressive effect of halofuginone on collagen 1(I)
mRNA gene expression [45]. The nature of the newly
synthesized protein(s) and how they function to de-
crease procollagen mRNA levels is unknown.
HALOFUGINONE IN ANIMAL MODELS OF CGVHD AND
SSC
Although there is no animal model that exhibits all
aspects of cGvHD or SSc [46], 2 experimental systems
are available that show many features resembling
those of the human disease [47]. The ﬁrst is murine
cGvHD, in which changes develop that are similar to
human cGvHD and SSc, including cutaneous ﬁbrosis,
loss of dermal fat, atrophy of dermal appendages,
deposition of mast cells, and mononuclear cell inﬁl-
tration [48]. The second model is the Tsk mouse
possessing a single gene mutation in the ﬁbrillin-1
gene on chromosome 2 [49]. The mutation is trans-
mitted as an autosomal dominant trait, whereas the
heterozygous Tsk/ mice develop coetaneous hyper-
plasia and connective tissue abnormalities in skin,
heart, and lungs [50,51] associated mainly with an
increase in collagen type I [52,53]. These mice pro-
duce autoantibodies characteristic of SSc patients [54].
In vitro halofuginone inhibited collagen produc-
tion by Tsk skin ﬁbroblasts by inhibition of the col-
lagen gene expression [44]. The reduction in collagen
synthesis preceded any effect on cell proliferation or
synthesis of other proteins, which suggests a speciﬁc
effect on the collagen biosynthesis pathway. In vivo
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halofuginone administered intraperitoneally elimi-
nated the increase in skin collagen and prevented the
thickening of the dermis and the loss of the subdermal
fat in both the cGvHD and the Tsk models in a
dose-dependent manner attributed to a decrease in
collagen type I gene expression [42]. These effects of
halofuginone were correlated with a decrease in the
number of cells expressing the collagen 1(I) gene
that reached the expression level of the matched con-
trols. Moreover, reductions in the levels of autoanti-
bodies speciﬁc for human target antigens (anti-topo-
isomerase I and antiﬁbrillin antibodies) were observed
[55]. These results raised an interesting question re-
garding the association of the ECM biosynthesis path-
way and autoimmunity. It has previously been sug-
gested that TGF- plays a critical role in ﬁbrosis and
is the pivotal immunoregulatory cytokine affecting the
immune responses by regulating monocyte function,
T-cell proliferation, and inﬂammation [56].
In an attempt to begin developing a local-therapy
modality for SSc and cGvHD, the effect of dermal
application of halofuginone on skin collagen and col-
lagen 1(I) gene expression in the Tsk mice was de-
termined. Dermal application of halofuginone (0.01%
in cream) for 60 days was equal to the systemic ad-
ministration (1 g per mouse per day) in reduction of
skin collagen 1(I) gene expression and was almost as
effective in reducing skin thickness. The effect of
halofuginone was time-dependent; 40 days of treat-
ment were needed for a signiﬁcant reduction in the
collagen 1(I) gene expression [43]. Physiologically,
skin ﬁbroblasts synthesize low levels of collagen. In
the Tsk mouse, the onset of ﬁbrosis coincides with the
presence of a large number of ﬁbroblasts expressing
elevated levels of collagen type I gene [57], as was
demonstrated in SSc [57,58]. The selective growth of
the subpopulation of ﬁbroblasts producing elevated
levels of collagen has been suggested to be the causes
of the ﬁbrotic condition [59]. These ﬁbroblasts are
probably the target for halofuginone [43]. The effect
of halofuginone was restricted to the dermis ﬁbro-
blasts and did not affect other proliferating, but col-
lagen-nonproducing cells, such as epidermal keratin-
ocytes.
TGF- PATHWAY, SMADS, AND FIBROSIS
TGF- is one of the leading candidates for elicit-
ing overproduction of ECM proteins in wound heal-
ing and in various ﬁbrotic conditions [60]. TGF-
meets the criteria of a major participant in ﬁbrosis: it
is present in the affected tissues, and it induces proﬁ-
brotic cellular and transcriptional responses such as
induction of the synthesis of ECM proteins, especially
collagen, as well as ﬁbronectin and laminin, and it
inhibits the matrix degradation enzymes [61]. Ele-
vated levels of TGF- were found in involved skin
lesions of SSc patients [62,63], in murine models of
sclerodermatous GvHD [64], and in the pathogenesis
of graft vascular disease [65]. There was association
between TGF- expression and severe GvHD in al-
logeneic bone marrow transplantation (BMT) [66].
TGF- is co-localized with collagen type I mRNA in
involved lesions in the early stages of inﬂammation
before the onset of ﬁbrosis and was implicated in the
initiation of ﬁbrosis in SSc [26]. Following binding of
TGF- to its receptor, signaling to the nucleus occurs
predominantly by phosphorylation of cytoplasmatic
mediators of the Smad family that are divided into 3
groups [60]. The regulation of matrix proteins in gen-
eral [67] and of collagen type I gene expression in
particular by TGF- involved the Smad3 signaling
pathway [68,69], and increased presence of nuclear
Smad3 has been observed in SSc ﬁbroblasts [70].
HALOFUGINONE AND TGF- PATHWAY
As a result of the extremely pleiotropic nature of
the effects of TGF-, therapies targeting the expres-
sion of the genes encoding TGF- or its receptors are
likely to be associated with an array of side effects
caused by abnormal cell proliferation, inﬂammation,
autoimmunity, and other potentially serious compli-
cations [71-73]. Drugs that selectively target individ-
ual signaling pathways downstream of the TGF-
receptor are, therefore, likely to be more successful.
Halofuginone was found to overcome the TGF-–
induced collagen synthesis in human skin ﬁbroblasts
[45] and ﬁbroblasts derived from control and Tsk
mice [44]. A similar inhibitory effect was observed on
promoter activity in ﬁbroblasts transfected with the
collagen 2(I) construct or with a construct with the
Smad binding site, which suggests that the target of
halofuginone is probably downstream in the TGF-
pathway. Although increased gene expression for
TGF- receptors was observed in SSc ﬁbroblasts [74],
no effect of halofuginone was observed on the expres-
sion of the TGF- receptors gene in the Tsk ﬁbro-
blasts, which further supports the hypothesis that
downstream effects were involved. Halofuginone was
found to inhibit phosphorylation of TGF-&beta–de-
pendent Smad3, but not that of Smad2, which resulted
in inhibition of Smad3 binding to DNA [44]. These
results demonstrate the speciﬁcity of halofuginone
activity, although the involvement of other members
of the Smad family in halofuginone-dependent inhi-
bition of collagen synthesis cannot be ruled out.
In most animal models of ﬁbrosis, regardless of the
tissue, halofuginone had a minimal effect on collagen
content in the control, nonﬁbrotic animals, whereas it
exhibited a profound inhibitory effect in the ﬁbrotic
organs. These results suggest a different regulation of
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the house-keeping and usually low level of expression
of collagen type I genes on one hand, and the over-
expression induced by the ﬁbrogenic stimulus, which
is usually an aggressive and a rapid process, on the
other. Halofuginone mainly affects the stimulated col-
lagen synthesis; therefore, when it was administered
systemically, it was actually targeted to the desired
ﬁbrotic location without affecting collagen synthesis
in other locations. In culture, halofuginone phosphor-
ylated Smad3 and was more effective in reducing col-
lagen synthesis by Tsk ﬁbroblasts after they had been
stimulated with a proﬁbrotic agonist such as TGF-;
whereas no effect on Smad3 phosphorylation and re-
duced effect on collagen synthesis was observed in
control cells [44].
HALOFUGINONE AFFECTS PREEXISTING FIBROSIS
In cGVHD and SSc, the skin is not the only organ
affected by ﬁbrosis; survival studies in SSc and
cGvHD patients have indicated a distinct dependency
on the involvement of internal organs [17,24]. In cases
of SSc, the prognosis was dependent on the involve-
ment of internal organs, particularly the lungs, heart,
and kidneys. Although the gastrointestinal tract is the
most frequently affected organ, its involvement is less
prognostic. As mentioned above, halofuginone has
been found to be efﬁcacious in inhibiting collagen
synthesis in multiple organs. In most of these studies,
halofuginone was used as a preventive agent; it was
administered before—or together with—the ﬁbrotic
stimulus [37-41]. In the Tsk mouse, halofuginone
treatment caused a decrease in the preexisting ﬁbrotic
condition as measured by changes in collagen gene
expression, collagen content, and skin morphology
[42-44]. In a liver ﬁbrosis model using rats with es-
tablished ﬁbrosis, halofuginone administration re-
sulted in complete resolution of the ﬁbrosis. The lev-
els of collagen, collagen 1(I) gene expression, and
-smooth muscle–positive cells, all of which are char-
acteristic of the ﬁbrotic condition, were reduced al-
most to the control levels [36]. Furthermore, liver
regeneration that was blocked in rats with established
ﬁbrosis occurred almost in a normal rate in halofugi-
none-treated rats [75].
HUMAN STUDIES FOR THE LOCAL TREATMENT OF
SSC AND CGVHD
A Phase I study with topical application of 0.1%
halofuginone was conducted in 14 healthy volunteers.
The results of the study showed safety and tolerability
following repeated topical applications of halofugi-
none cream. There was no skin irritation or systemic
absorption of halofuginone (Dr. S. Tamin, unpub-
lished data, 1998). As a proof of principle, halofugi-
none cream was locally applied on the skin of a 22-
year-old male with acute promyelocytic leukemia who
underwent successful BMT from his HLA-matched
brother. Three-and-a-half months after BMT, he de-
veloped severe, extensive, de novo cGvHD with skin,
mucosal, gastrointestinal tract, and liver involvement.
The skin cGvHD was manifested by scattered lichen-
oid papules and mottled hyperpigmentation, mainly of
the neck and upper chest and back, as well as of both
axillae, lower abdomen, and ﬂanks. Oral examination
disclosed severe lichenoid lesions with hypertrophy of
all the buccal and labial mucosa, atrophy of the papil-
lae of the tongue with oral pain, xerostomia, and loss
of taste. The skin cGvHD progressed, and within 8
months, the patient developed severe bilateral sclero-
sis and tightening of the skin of the neck resembling
sclerodermoid changes that then progressed to con-
tractures with pain and limitation of movements [76].
The protocol included once-daily topical application
of 0.03% halofuginone ointment to the left side of the
neck and the posterior aspect of the left shoulder for a
period of 6 months, while the right and corresponding
side served as control. After 1 month, softness of the
left side of the neck and upper back was noted by
clinical observation. There was no itching, rash, or
erythema. Over the next few weeks, the softness in-
tensiﬁed and was accompanied by gradual loosening of
the sclerosis and tightness in the left side of the neck.
In comparison, no change was observed in the un-
treated, control right side. No change in the skin
pigmentation was noticed on either side. Within 3
months, there was an improvement in the pain and
dysphagia, most probably related to the improvement
in the severe sclerosis and ﬁbrosis of the neck, and
after 6 months of therapy rotation of the neck, only to
the treated side, had improved from 30% to 70%.
Skin biopsies were taken pretherapy from clinically
involved and uninvolved areas at the left and right
upper back below the scapulas, from the involved-
treated areas after 3 and 6 months of topical halofugi-
none therapy and 3 months following termination of
halofuginone treatment [76]. The level of collagen
1(I) gene expression and the collagen content were
much higher in the affected area compared with the
macroscopically nonaffected area. Three months of
halofuginone treatment caused a marked decrease in
collagen 1(I) gene expression and collagen content,
and a further decrease in both parameters was ob-
served after an additional 3 months of treatment (Fig-
ure 1). However, 3 months after cessation of treat-
ment, the levels of collagen 1(I) gene expression
returned almost to baseline levels, indicating that the
halofuginone-mediated inhibitory effect of collagen
synthesis is reversible [76]. The transient effect of
halofuginone was probably the result of the chronic
process providing a continuing stimulus to ﬁbrogen-
esis. Throughout the treatment period, there was no
Halofuginone, cGvHD, and SSc
421BB&MT
local or systemic toxicity, and no side effects were
noticed. Repeated blood biochemistry tests of liver
and kidney functions did not disclose any changes
from the pretreatment values, blood counts were nor-
mal, and no halofuginone could be detected in the
patient’s sera (high-performance liquid chromatogra-
phy assay sensitivity for halofuginone is 1 ng/mL), all
of which suggest that topical application of halofugi-
none is safe and will not cause any systemic effects in
other locations.
A phase II trial was performed to assess the safety
and efﬁcacy of halofuginone in diffuse SSc patients
with changes in the upper extremities resulting in a
modiﬁed Rodnan skin score of at least 10/21. The
modiﬁed Rodnan skin thickness score measured on a
0-3 scale (0, normal; 1, mild thickness; 2, moderate
thickness; 3, severe thickening) of 7 regions of the
upper extremity was used [77]. Thirteen patients were
treated once daily with topical application of 0.01%
halofuginone on either left or right upper extremities
(hand, forearm, upper arm). Eleven of these patients
completed a 6-month treatment period. Safety results
showed that there were no clinically relevant changes
in vital signs (blood pressure, heart rate, body temper-
ature, and body weight) and laboratory evaluations
that included hematology (red blood cell, white blood
cell, and platelet counts, hemoglobin, and hematocrit)
and clinical chemistry (creatine phosphokinase, aspar-
tate transaminase, -glutamyl transferase, lactose de-
hydrogenase, albumin, total and indirect bilirubin,
urea, creatinine, glucose, sodium, and potassium). The
most frequently reported adverse event that was at-
tributed to the treatment was dermatitis of varying
degree and severity observed macroscopically that did
not dictate cessation of the treatment. Efﬁcacy evalu-
ation results (changes in total skin score from baseline
by 2 raters) showed a statistically signiﬁcant reduction
in the mean total skin score after 3 months of treat-
ment (Table 1). Of 12 patients, 5 met responder cri-
teria of at least 25% reduction in the total skin score
in the treated arm, and the mean time for response was
2.6 months. The results of the human safety and
efﬁcacy studies provide a basis for the proof of concept
of using halofuginone as the drug for treatment of
dermal ﬁbrosis and paved the way for a phase III
placebo-controlled, double-blind trial.
Figure 1. Collagen 1(I) gene expression. Skin biopsies were taken from the posterior upper back of the cGvHD patient before (A) and 6
months after (B) topical halofuginone therapy. The sections were hybridized with digoxigenin-labeled collagen 1(I) probe. Note the reduction
in cells expressing the collagen 1(I) gene (arrows).
Table 1. Total Skin Score of the Treated Arm of Responders and
Nonresponders
Time of
Treatment
(months)
Total Skin Score (Means  STD)
Efficacy-Eligible
Patients
(n  12)
Nonresponders
(n  7)
Responders
(n  5)
Baseline 12.5  2.4 13.1  2.2 11.7  2.6
Baseline 11.8  2.0 12.0  1.7 11.5  2.6
1 10.0  4.5 12.1  1.9 7.2  5.7
2 10.8  4.0 12.4  2.3 8.7  5.2
3 9.6  3.6 10.9  2.0 8.2  4.4
4 10.4  2.9 12.7  1.2 8.6  3.4
6 10.1  3.7 11.3  1.8 8.6  5.0
Haloluginone caused a signiﬁcant (P  0.03) reduction in the
mean total skin score of the efﬁcacy-eligible patients after 3 months
of treatment compared with baseline.
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PHARMACOKINETICS AND SAFETY: ORAL
FORMULATION
An ascending, single, oral-dose Phase I study in
healthy volunteers was performed to assess the safety,
tolerability, and pharmacokinetics of orally adminis-
tered halofuginone. The study was double-blind in a
single center and involved 26 healthy, male volun-
teers. The doses tested were between 0.07 to 2.5
mg/d, and the drug was given with food during diet-
controlled meals. Single, oral doses of 0.07 and 0.5 mg
halofuginone were found to be safe and well tolerated.
No clinically signiﬁcant adverse events were recorded
in these groups, whereas simulated steady state from
the 0.5-mg group surpassed the predicted therapeutic
exposure. At 1.5 to 2.5 mg, halofuginone was moder-
ately tolerated, with incidence of gastrointestinal ad-
verse events (nausea and vomiting) associated with
dose increments. A daily dose of 1.5 mg halofuginone
was designated as the maximal tolerated dose. To
improve the tolerability proﬁle of orally administered
halofuginone, a 3-way, crossover, split-dose study in 8
male volunteers was initiated in which 3 dose regi-
mens (0.25 mg  8; 0.5 mg  4 or 2.0 mg  1) were
assessed. Dividing the dose into several daily portions,
thereby reducing the slope increment of plasma levels
of halofuginone, allowed the exposure to be increased
without increasing gastrointestinal adverse events.
CONCLUSION
Any perturbation in the cellular function of any
tissue that causes excessive collagen deposition and
results in ﬁbrosis may be a target for halofuginone
therapy. Because halofuginone inhibited collagen type
I synthesis on the transcriptional level and an increase
in the ECM degradation capabilities, it is a promising
candidate for treatment of diseases caused by, or as-
sociated with, excessive ECM, such as SSc and
cGvHD. The local application of halofuginone is safe,
without indications of systemic absorption. Systemi-
cally, therapeutically effective plasma levels can be
reached at a dosage that is tolerated. Thus, halofugi-
none meets the criteria as a potential antiﬁbrotic drug
for further evaluation in the treatment of cGvHD.
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